Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com. 

Therapeutics

Life Sciences

Biotechnology

Merida Biosciences

The Cambridge office focuses on innovative life sciences research and development, encompassing various scientific and managerial roles.

People (23)

Jobs (0)

Other offices